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BACKGROUND
The relationship between the risk of celiac disease and both the age at which 
gluten is introduced to a child’s diet and a child’s early dietary pattern is unclear.
METHODS
We randomly assigned 832 newborns who had a first-degree relative with celiac 
disease to the introduction of dietary gluten at 6 months (group A) or 12 months 
(group B). The HLA genotype was determined at 15 months of age, and serologic 
screening for celiac disease was evaluated at 15, 24, and 36 months and at 5, 8, and 
10 years. Patients with positive serologic findings underwent intestinal biopsies. 
The primary outcome was the prevalence of celiac disease autoimmunity and of 
overt celiac disease among the children at 5 years of age.
RESULTS
Of the 707 participants who remained in the trial at 36 months, 553 had a stan-
dard-risk or high-risk HLA genotype and completed the study. At 2 years of age, 
significantly higher proportions of children in group A than in group B had celiac 
disease autoimmunity (16% vs. 7%, P = 0.002) and overt celiac disease (12% vs. 5%, 
P = 0.01). At 5 years of age, the between-group differences were no longer significant 
for autoimmunity (21% in group A and 20% in group B, P = 0.59) or overt disease 
(16% and 16%, P = 0.78 by the log-rank test). At 10 years, the risk of celiac disease 
autoimmunity was far higher among children with high-risk HLA than among 
those with standard-risk HLA (38% vs. 19%, P = 0.001), as was the risk of overt 
celiac disease (26% vs. 16%, P = 0.05). Other variables, including breast-feeding, were 
not associated with the development of celiac disease.
CONCLUSIONS
Neither the delayed introduction of gluten nor breast-feeding modified the risk of 
celiac disease among at-risk infants, although the later introduction of gluten was 
associated with a delayed onset of disease. A high-risk HLA genotype was an im-
portant predictor of disease. (Funded by the Fondazione Celiachia of the Italian 
Society for Celiac Disease; CELIPREV ClinicalTrials.gov number, NCT00639444.)
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Celiac disease is a systemic immune-mediated disorder caused by the ingestion of gluten-containing grains (wheat, rye, 
and barley) in genetically susceptible persons. It 
is one of the most common lifelong disorders, 
affecting approximately 1% of the population in 
Europe and North America1,2; the prevalence of 
this disease is higher among persons who have 
first-degree relatives with celiac disease (10 to 
15%).3,4 The prevalence of celiac disease has in-
creased in developed countries over recent decades; 
this finding points to the role of one or more pos-
sible environmental triggers other than gluten.5
Genetic background plays a key role in the 
predisposition to celiac disease. The HLA-DQ2 
(DQA1*0501-DQB1*0201) haplotype is expressed 
in the majority of affected patients (90%), the 
DQ8 haplotype (DQA1*0301-DQB1*0302) is ex-
pressed in 5%, and 5% carry at least one of the 
two DQ2 alleles (usually the DQB1*0201). An in-
creased risk of celiac disease has been observed 
among persons who carry two DQB1*02 alleles.6,7 
Gluten is required to trigger the disease, but the 
interplay between genetic and environmental fac-
tors regulating the balance between tolerance 
and immune response to gluten is still poorly 
understood. It has been hypothesized that intes-
tinal infections, the amount and quality of in-
gested gluten, the composition of intestinal micro-
biota, and infant-feeding practices are all possible 
triggers of the switch from tolerance to an im-
mune response to gluten.1
The introduction of gluten at 6 months of age 
is a long-standing practice.8 Despite the fact that 
the “gluten at 6 months” rule is deeply rooted in 
many developed countries, the optimal timing of 
the introduction of gluten in the infant’s diet has 
not been rigorously tested. Many clinicians ad-
vise that the introduction of gluten to the diet of 
infants who have a familial risk of the disease 
should be delayed. Depending on timing, this 
delay may permit the maturation of the small 
intestinal barrier and the mucosal immune re-
sponse.9,10 However, investigations of the epi-
demic of celiac disease that occurred in Sweden 
during the 1980s and 1990s indicate that the in-
troduction of a small amount of gluten during 
breast-feeding of infants between 4 and 6 months 
of age reduces the risk of disease.11,12 Studies in-
volving infants at genetic risk for type 1 diabetes 
suggest that the risk of type 1 diabetes or celiac 
disease is increased among infants who began 
to receive gluten either before 4 months or after 
7 months of age; this provides support for the 
view that there is a window of time, between 
4 and 7 months, during which the introduction of 
gluten might facilitate induction of tolerance.13-15
To clarify the relationship between the age at 
which gluten is introduced to a child’s diet and 
the risk of celiac disease, we undertook the Risk 
of Celiac Disease and Age at Gluten Introduction 
(CELIPREV) trial, a multicenter, prospective inter-
vention trial comparing early and delayed introduc-
tion of gluten to the diet of infants with a famil-
ial risk of celiac disease, and we followed these 
children from birth to at least 5 years of age.
Me thods
Patients and Study Design
Newborns who had a familial risk of celiac disease 
(i.e., newborns who had at least one first-degree 
relative with celiac disease) were recruited at 20 
centers in Italy between 2003 and 2008. Infants 
were assigned on the basis of block randomiza-
tion to one of two groups: those in group A were 
assigned to the introduction of food containing 
gluten (pasta, semolina, and biscuits) at 6 months 
of age, and those in group B were assigned to the 
introduction of food containing gluten at 12 
months of age. The primary outcome was the 
prevalence of celiac disease autoimmunity and of 
overt celiac disease among patients with a stan-
dard-risk or high-risk HLA genotype according 
to trial group at 5 years of age.
At 12 months of age, all children began to 
receive a normal diet containing gluten. Inter-
views were conducted to obtain information on 
the diet and intestinal infections during the first 
year of life. The daily intake of cereal containing 
gluten (wheat, rye, and barley) was assessed by 
means of a 24-hour dietary-recall questionnaire, 
and daily gluten intake was calculated as the sum 
of grams of protein obtained from gluten-related 
grains multiplied by 0.8.16 A workup for celiac 
disease was performed at 15 months of age (IgA 
antitransglutaminase type 2 [TGA2], IgA anti-
gliadin antibodies, total IgA, and HLA-DQ2 and 
HLA-DQ8 genotype), at 24 months (TGA2 and 
antigliadin antibodies), and at 3, 5, 8, and 10 
years (TGA2). In children with IgA deficiency 
(IgA <5 mg per deciliter), we tested for the pres-
ence of IgG antigliadin antibodies. Children with 
positive serologic results were recalled for repeti-
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tion of the test and determination of the presence 
of endomysial antibodies. A small-bowel biopsy 
was recommended for children with seropositiv-
ity for celiac disease autoimmunity (i.e., positive 
results for IgA TGA2 and endomysial antibodies, 
positive results for IgG antigliadin antibodies with 
IgA deficiency, or positive results for IgA antiglia-
din antibodies in children younger than 2 years 
of age). We defined overt celiac disease as celiac 
disease autoimmunity and a Marsh classification 
of 2 or 3 at small-bowel biopsy (on a scale of 0 to 
3, with higher scores indicating villous atrophy), 
and potential celiac disease as celiac disease au-
toimmunity and a Marsh classification of 0 or 1. 
Children with overt celiac disease began to receive 
a gluten-free diet, and those with potential celiac 
disease continued to receive a normal diet unless 
they had symptoms. Findings from the 2-year 
follow-up of a subgroup of children with potential 
celiac disease were reported in a previous study.17
The study protocol was approved by the insti-
tutional review board at each participating center. 
Written informed consent was obtained from the 
parents or guardians of the children.
All the authors vouch for the accuracy of the 
data and analyses reported and the fidelity of the 
study to the protocol. The study protocol is avail-
able with the full text of this article at NEJM.org.
HLA Genotyping
The detection of HLA alleles was performed with 
the use of the DQ-CD Typing Plus kit (BioDia-
gene), and on the basis of this assessment, the 
children were classified as having no risk of ce-
liac disease (the absence of HLA-DQ2 and HLA-
DQ8), a standard risk of celiac disease (a single 
or double copy of the DQB1*02 allele associated 
with DQA1 alleles different from the DQA1*05, 
or a single DQ2 [DQA1*05-DQB1*02] either in cis 
or trans position, or DQ8 [DQA1*03-DQB1*0302/ 
0305] haplotypes), or a high risk of celiac dis-
ease (homozygosity for DQA1*05-DQB1*02 or 
DQA1*05-DQB1*02-DQA1*0201-DQB1*02).18,19
Serologic Assays
All serum samples were kept frozen at −20°C 
until analysis in a single laboratory at Udine 
Hospital, Udine, Italy. Serum IgA TGA2 was 
measured by means of an enzyme-linked immu-
nosorbent assay (ELISA) with the use of a com-
mercial kit (Menarini Diagnostics). More than 
20 arbitrary units indicated a positive result. IgA 
antigliadin antibodies and IgG antigliadin anti-
bodies were measured by means of ELISA with the 
use of a commercial kit (Menarini Diagnostics); 
more than 15 arbitrary units indicated a positive 
result. Endomysial antibodies were detected by 
means of indirect immunofluorescence, with the 
use of monkey esophagus as substrate (a titer of 
1:10 or higher that resulted in a positive reaction 
was considered to be positive), and total serum 
IgA was measured by means of nephelometry.
Diagnosis of Overt Celiac Disease
Small-bowel biopsies were performed by means 
of upper endoscopy, and at least four specimens 
were obtained from the bulb and the descending 
part of the duodenum. The ratio of villous height 
to crypt depth was measured, and a ratio of 2 or 
Variable
Group A 
(N = 297)
Group B 
(N = 256)
Median age — yr 7.8 7.9
Female sex — no. (%) 146 (49.2) 128 (50.0)
First­degree relatives with celiac disease 
 — no. (%)
Type of relative
Father 23 (7.7) 16 (6.2)
Mother 95 (32.0) 112 (43.8)
Brother 59 (19.9) 63 (24.6)
Sister 91 (30.6) 44 (17.2)
No. of relatives
1 268 (90.2) 235 (91.8)
2 25 (8.4) 19 (7.4)
3 4 (1.3) 2 (0.8)
Breast­fed — no. (%) 193 (65.0) 178 (69.5)
Duration of breast­feeding — mo 5.9±5.4 6.4±6.4
Breast­fed during introduction of gluten 
 — no. (%)†
84 (28.3) 29 (11.3)
Intake of gluten — g/day
At 9 mo† 3.2±1.5 0
At 15 mo 6.5±2 6.8±2
Age at introduction of gluten — mo† 6.1±0.9 12.2±0.9
HLA genotype — no. (%)
Standard risk 265 (89.2) 230 (89.8)
High risk 32 (10.8) 26 (10.2)
*  Plus–minus values are means ±SD. The difference between the groups was 
assessed with the use of Student’s t­test and the chi­square test.
†  P<0.001 for the comparison between the groups.
Table 1. Characteristics of the Participants.*
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more was considered normal. Intraepithelial lym-
phocytosis was defined as more than 25 in-
traepithelial lymphocytes per 100 epithelial cells. 
Lesions in the small intestine were graded at the 
coordinating center in Ancona, Italy, according to 
the Marsh classification.20 The graders were not 
informed of the group assignments.
Statistical Analysis
The analysis included all randomly assigned chil-
dren classified according to their assigned diet. 
Participants with missing data on serologic out-
comes were included in the final analysis if at 
least one serologic result was available at 36 months 
of follow-up or thereafter; participants who were 
lost to follow-up before 36 months or for whom 
we had no serologic data were excluded from the 
analysis.
Data are expressed as means ±SD. Proportions 
were compared with the use of the chi-square test 
with Yates’ correction for continuity or Fisher’s 
exact test as appropriate; comparison of continu-
ous variables was performed with the use of Stu-
dent’s t-test. Kaplan–Meier curves were plotted 
for the primary end point (i.e., the risk of celiac 
disease according to age and trial group) and the 
secondary end point (i.e., the risk of celiac disease 
according to trial group in a single prespecified 
subgroup of interest [children with high-risk HLA 
genotypes]). Differences between these curves 
were assessed with the use of log-rank tests and 
proportional-hazards models. All differences were 
considered to be statistically significant at a 5% 
probability level, and all reported P values are two-
sided. Risk models were developed with the use 
of decision-tree induction from class-labeled train-
ing records (i.e., the training set was composed 
of records in which one attribute was the class 
label [or dependent variable] and the remaining 
attributes were the predictor variables; the indi-
vidual records are the tuples for which the class 
label is known), as previously described.17,21 Sta-
tistical analysis was performed with the use of 
tools for survival analysis and recursive partition-
ing analysis within the R system.
R esult s
Patients
Data on enrollment and study-group assignments 
are shown in Figure S1 in the Supplementary Ap-
pendix, available at NEJM.org. After exclusion of 
125 patients who dropped out, the cohort included 
707 infants (379 in group A and 328 in group B). 
There were 351 girls (49.6%), and the median 
age of the cohort was 7.9 years (range, 5.2 to 10.6) 
in October 2013, when the study was terminated. 
The primary reason for the imbalance between 
groups with respect to the number of participants 
in this multicenter study was our inability to fully 
control the higher patient dropout rate in group B 
soon after randomization. By the end of the study, 
all children were at least 5 years of age, 75% were 
7 years of age, 49% were 8 years of age, and 16% 
were 10 years of age. Of the 707 infants tested 
for HLA status, 154 were in the HLA no-risk group 
(21.8%) and were excluded from further analysis. 
The final study group included 553 children who 
were positive for HLA-DQ2, HLA-DQ8, or both 
(Table 1).
We obtained serologic data from all 553 chil-
dren at 15 months of age and from 536 children at 
24 months of age (97%), 487 children at 36 months 
of age (88%) (by which point 66 of the 553 chil-
dren in the final study group had overt celiac dis-
ease and were therefore not tested for celiac dis-
ease autoimmunity), 451 children at 5 years of age 
(82%), 373 children at 7 years of age (67%), 267 
children at 8 years of age (48%), and 89 children 
at 10 years of age (16%). Overall, 122 children had 
positive serologic results, but only 117 fulfilled 
the criteria for small-bowel biopsy; the other 5 had 
isolated, low-titer TGA2 positivity. Of the 117 
children with celiac disease autoimmunity, 113 
were positive for TGA2 and endomysial anti-
bodies, 3 were positive for IgG antigliadin anti-
Figure 1. Kaplan–Meier Estimates of Overt Celiac Disease in Children  
with High-Risk HLA Genotypes, According to Age.
Dashed lines represent 95% confidence intervals.
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bodies with IgA deficiency, and 1 was positive for 
IgA antigliadin antibodies. Of these 117 children, 
112 underwent small-bowel biopsy; the parents 
of the remaining 5 children (all of whom were 
positive for TGA2 and endomysial antibodies) in-
stituted a gluten-free diet. These 5 patients were 
all symptomatic, and their symptoms improved 
with the use of a gluten-free diet; therefore, they 
were included in the group of children with overt 
celiac disease. Of the 112 children who under-
went biopsy of the small intestine, 86 had a Marsh 
classification of 2 or higher (5 children had a 
score of 2, 6 had a score of 3a, 33 had a score of 
3b, and 42 had a score of 3c) and received a diag-
nosis of overt celiac disease. A total of 26 chil-
dren had a Marsh classification of 0 (15 children) 
or 1 (11 children) and received a diagnosis of po-
tential celiac disease. A 4-year follow-up assess-
ment after the first biopsy showed that 19 of 
these 26 children had normalization of serum 
antibody levels, 2 had fluctuating antibody lev-
els, and 3 had begun to receive a gluten-free diet 
on the basis of parental choice. The other 2 had 
undergone biopsy a second time and been found 
to have lesions with a Marsh classification of 3; 
they were therefore reclassified as having overt 
celiac disease.
Study Outcomes
Overall, at 10 years of age, among children with 
a familial risk of celiac disease, the prevalence of 
celiac disease autoimmunity was 16.5% (in 117 
of 707 children) and the prevalence of overt ce-
liac disease was 13.2%. At the age of 10 years, 
among children who were found to have a famil-
ial risk and a celiac disease–predisposing HLA 
genotype in infancy, the prevalence of celiac dis-
ease autoimmunity was 21.1% and the prevalence 
of overt celiac disease was 16.8% (Fig. 1). Celiac 
disease autoimmunity developed in 37.9% of chil-
dren with high-risk HLA genotypes as compared 
with 19.2% of children with standard-risk HLA 
genotypes (hazard ratio, 0.5; 95% confidence 
interval [CI], 0.3 to 0.7; P = 0.001) (Fig. S2A in the 
Supplementary Appendix). Overt celiac disease 
developed in 25.8% of children with high-risk 
HLA genotypes as compared with 15.8% of chil-
dren with standard-risk HLA genotypes (hazard 
ratio, 0.6; 95% CI, 0.3 to 1.0; P = 0.05) (Fig. S2B in 
the Supplementary Appendix).
Figure 2 shows the proportion of children in 
whom overt celiac disease and celiac disease au-
toimmunity developed, according to study group. 
At 2 years of age, the proportion of children with 
overt celiac disease was significantly higher in 
group A than in group B (12% vs. 5%, P = 0.01). 
However, this difference had resolved by 5 years 
of age (16% vs. 16%; hazard ratio for the devel-
opment of overt celiac disease, 0.9; 95% CI, 0.6 to 
1.4; P  = 0.78) and was not observed at 8 or at 10 
years of age (hazard ratio at 10 years, 0.9; 95% 
CI, 0.6 to 1.4; P = 0.79). The median age at diag-
nosis of overt celiac disease was 26 months in 
group A and 34 months in group B (P = 0.01).
There was a significantly greater prevalence of 
celiac disease autoimmunity in group A than in 
group B at 2 years of age (16% vs. 7%, P = 0.002), 
and the difference had resolved by 5 years of age 
(21% and 20%, respectively; P = 0.59). In children 
Figure 2. Kaplan–Meier Estimates of Celiac Disease Autoimmunity (CDA) 
and Overt Celiac Disease, According to Study Group.
Pr
op
or
tio
n 
of
 C
hi
ld
re
n 
w
ith
O
ve
rt
 C
el
ia
c 
D
is
ea
se
1.0
0.6
0.8
0.4
0.2
0.0
0 2 4 6 8 10
Years of Age
B
A
Hazard ratio at 5 yr, 0.9 (95% CI, 0.6–1.4)
P=0.78
No. at Risk
Group A
Group B
297
256
282
254
250
237
221
195
148
119
8
5
Pr
op
or
tio
n 
of
 C
hi
ld
re
n 
w
ith
 C
D
A
1.0
0.6
0.8
0.4
0.2
0.0
0 2 4 6 8 10
Years of Age
Hazard ratio at 5 yr, 0.9 (95% CI, 0.6–1.3)
P=0.59
No. at Risk
Group A
Group B
297
256
282
254
250
237
221
195
148
119
8
5
Group A
Group A
Group B
Group B
Overt Celiac Disease
CDA
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA STUDI DI TORINO on November 17, 2015. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
n engl j med 371;14 nejm.org October 2, 20141300
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
with high-risk HLA alleles, the prevalence of ce-
liac disease autoimmunity was greater in group 
A than in group B at all ages, but the difference 
was not significant (P = 0.51) (Fig. 3).
The clinical characteristics of children with 
and those without celiac disease are shown in 
Table 2. During follow-up, celiac disease–related 
complications (i.e., autoimmune thyroid disease, 
type 1 diabetes, or both) did not develop in any 
of the children. The result of the decision-tree 
analysis for prediction of celiac disease autoim-
munity and overt celiac disease is shown in Fig-
ures S3A and S3B in the Supplementary Appen-
dix. The lowest-risk branch (leading to no celiac 
disease instead of celiac disease autoimmunity 
or overt celiac disease) was assigned to children 
with a standard-risk HLA genotype. None of the 
other variables studied had a significant effect in 
predicting the development of celiac disease. A 
Cox proportional-hazards model confirmed the 
decision-tree analysis of the contribution of each 
factor to the development of celiac disease (Ta-
bles S1A and S1B in the Supplementary Appendix).
Discussion
We found that postponing the introduction of 
gluten until 12 months of age had no effect on 
the risk of the development of celiac disease in 
the long term. This result was consistent with the 
finding that delaying gluten exposure until the 
age of 12 months is safe but does not substan-
tially reduce the risk of islet autoimmunity in 
children who are genetically at risk for type 1 
diabetes.22 Postponing the introduction of gluten 
had two potentially positive consequences. First, 
it delayed the development of celiac disease, which 
might reduce the negative effect of the disease 
on vulnerable organs such as the brain. Second, 
it reduced the prevalence, albeit nonsignificantly, 
of celiac disease autoimmunity at any age among 
children carrying the high-risk HLA genotype 
(Fig. 3). This finding provides support for Kon-
ing’s HLA–gene dose model, which posits that 
targeted prevention of celiac disease in high-risk 
HLA infants prevents the development of uncon-
trolled T-cell responses to the high numbers of 
immunogenic HLA DQ2–gluten complexes.23
The concept of a window of gluten tolerance 
gained popularity after U.S. investigators report-
ed in 2005 that at-risk children exposed to gluten 
at 4 to 6 months of age had a reduced risk of ce-
liac disease, as compared with those exposed to 
gluten before 4 months or after 7 months of age, 
but the number of patients with biopsy-proven 
celiac disease in their study was small.14 German 
infants with a familial risk of type 1 diabetes 
whose first dietary exposure to gluten occurred 
after the age of 6 months did not have an in-
creased risk of celiac disease autoimmunity or 
islet autoantibodies.24 A Norwegian study25 that 
matched dietary data collected in a nationwide, 
prospective, questionnaire-based survey with the 
presence or absence of celiac disease showed 
only a minimally increased risk of celiac disease 
among infants introduced to gluten after 6 months 
of age, and adjusted analyses did not show an as-
sociation between the early introduction of gluten 
(before 4 months of age) and an increased risk 
of celiac disease. The Norwegian study included 
only children with clinically diagnosed celiac dis-
ease, so its results do not necessarily apply to the 
overall population of persons with celiac dis-
ease. Our data showed no difference in the risk 
of celiac disease between children who were in-
troduced to gluten at 6 months (during the open 
“window”) and those who were introduced to 
gluten at 12 months (when the window was 
closed). Thus, our findings do not support the 
“window of tolerance” hypothesis.
Our study sheds light on other aspects of the 
relationship between infant nutrition and the risk 
of celiac disease. A protective role of breast-feed-
ing has long been claimed, mostly based on a few 
Figure 3. Kaplan–Meier Estimates of CDA in Children with a Celiac  
Disease–Predisposing HLA Genotype, According to Study Group.
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observational, retrospective studies,26-29 which were 
summarized in a meta-analysis30 and a system-
atic review.31 These surveys did not clarify wheth-
er breast-feeding provides permanent protection 
against celiac disease or simply delays the onset 
of symptoms. The Norwegian study25 not only did 
not support a protective effect of breast-feeding 
but also showed an unexpected association be-
tween breast-feeding that was prolonged beyond 
12 months of age and an increased risk of celiac 
Variable
Celiac Disease 
Autoimmunity 
(N = 117)
Overt Celiac 
Disease  
(N = 93)
No Celiac 
Disease 
(N = 436)
Female sex — no. (%) 65 (55.6) 54 (58.1) 209 (47.9)
First­degree relatives with celiac disease — no. (%)
Type of relative
Father 9 (7.7) 8 (8.6) 30 (6.9)
Mother 46 (39.3) 34 (36.6) 161 (36.9)
Brother 17 (14.5) 14 (15.1) 85 (19.5)
Sister 33 (28.2) 24 (25.8) 121 (27.8)
No. of relatives
1 105 (89.7) 80 (86.0) 397 (91.1)
2 10 (8.5) 11 (11.8) 33 (7.6)
3 2 (1.7) 2 (2.2) 6.0 (1.4)
Duration of breast­feeding — mo 5.6±6.3 6.0±6.5 5.8±5.8
Breast­fed during introduction of gluten — no. (%) 23 (19.7) 19.0 (20.4) 87.0 (20.0)
Intake of gluten at 15 mo — g/day 6.5±2.0 6.5±2 6.7±2.0
Age at introduction of gluten — mo 8.8±3.2 9.0±3.2 8.9±3.2
Introduction of gluten — no. (%)
At 6 mo, group A 64 (54.7) 50 (53.8) 234 (53.7)
At 12 mo, group B 53 (45.3) 43 (46.2) 203 (46.6)
Enteritis, one or more episodes from 0 to 15 mo of age  
— no./total no. (%)†
5/58 (8.6) 3/42 (7.1) 29/249 (11.6)
Elevated antibody level at diagnosis — ×ULN
TGA2 IgA 9.9±9.3 11.1±9.8 —
Antigliadin IgA 3.8±6.9 4.5±7.6 —
Symptoms of celiac disease — no. (%)
Typical 46 (39.3) 46 (49.5) —
Atypical 10 (8.5) 10 (10.8) —
None 61 (52.1) 37 (39.8) —
HLA genotype — no. (%)
Standard risk‡ 91 (77.8) 78 (83.9) 400 (91.7)
High risk 26 (22.2) 15 (16.1) 36 (8.3)
*  Plus–minus values are means ±SD. The difference between the groups was tested by means of Student’s t­test and the 
chi­square test. ULN denotes upper limit of the normal range.
†  Data on enteritis were available for only 307 children. The diagnosis of enteritis was based on the presence of diarrhea 
associated with infectious disease.
‡  P = 0.03 for the comparison between the group with overt celiac disease and the group with no celiac disease, and 
P<0.001 for the comparison between the group with celiac disease autoimmunity and the group with no celiac disease.
Table 2. Characteristics of Children with Celiac Disease Autoimmunity, Those with Overt Celiac Disease, and Those 
without Celiac Disease.*
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disease. We did not detect an effect of breast-
feeding on the development of celiac disease: the 
mean duration of breast-feeding was very similar 
for at-risk children among whom celiac disease 
developed and at risk-children among whom the 
disorder did not develop (5.6 and 5.8 months, re-
spectively). We did not observe a protective effect 
of introducing gluten during breast-feeding, but 
our study was not designed to address this issue, 
which was evaluated in the European PreventCD 
study, which is reported by Vriezinga et al. in this 
issue of the Journal.32
We diagnosed celiac disease autoimmunity 
and overt celiac disease according to current 
guidelines.33,34 The high prevalence of celiac dis-
ease autoimmunity by 5 years of age that we 
observed could indicate that the “epidemic” of 
celiac disease is continuing its upward trend, 
since it is known that celiac disease can develop 
in persons of any age, including the elderly.5 Our 
estimate of the prevalence of celiac disease auto-
immunity included patients with potential celiac 
disease, many of whom had a loss of antibodies 
with a normal diet, over the course of time. The 
long-term prognosis for children with transient 
celiac disease autoimmunity remains to be estab-
lished; overt celiac disease could develop in some 
of them over time.35
It is possible that we underestimated the num-
ber of children in whom celiac disease developed 
because of incomplete follow-up, but overt celiac 
disease developed in the large majority of chil-
dren within the first 5 years of life, and in 80% 
of those in whom celiac disease developed, it did 
so during the first 3 years. We therefore suggest 
that efficient screening for celiac disease may be 
carried out by testing school-age children. Our 
results support early determination of the HLA-
DQ haplotype in infants with a familial risk of 
celiac disease, not only to exclude infants who are 
negative for HLA-DQ2 and HLA-DQ8 from fur-
ther investigation but also to identify those with 
two copies of the HLA-DQ2 allele, who require 
close monitoring because of the high risk of dis-
ease36 (38% in our at-risk cohort).
The high-risk HLA genotype was the only factor 
that was significantly associated with the devel-
opment of celiac disease autoimmunity and overt 
celiac disease in the decision-tree analysis: other 
variables (type of relative with celiac disease, 
number of affected relatives, dietary pattern, and 
early intestinal infections) showed no association 
with disease risk.
In conclusion, our study suggests that celiac 
disease autoimmunity tends to develop in geneti-
cally predisposed children early in life, usually 
before the age of 5 years. Early dietary factors, 
particularly the child’s age at the introduction of 
gluten, seem to play a minor role in the risk of 
the development of celiac disease. However, de-
laying the introduction of gluten in at-risk infants 
may delay the onset of the disease, with potential 
benefit related to maintenance of a state of health 
during a crucial period of child development.
Although there are many good reasons to 
recommend prolonged breast-feeding of children, 
regardless of whether they have a genetic risk for 
the development of celiac disease, we did not 
discern a protective effect against celiac disease. 
Additional studies are needed to establish wheth-
er key environmental factors, such as the com-
position of microbiota, metabolic profile, vacci-
nation schedule, and use of antibiotics, affect the 
tolerance–immune response equilibrium in these 
at-risk infants during the first 5 years of life.
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